TNBC - MOA and combination studies as pre-clinical.
By
TNBC - MOA and combination studies as pre-clinical.
By 48 month follow-up, we will have had the data for close to 1 year.
This time me says no FDA application/ approval of any kind for a while related to mTNBC.
Dr. J initially said potentially significant partner/and or approval. To potential partner/approval with possibly a funding raise. I combine that with Dr. Pestell going to 2nd conference in July --- my "May" or within weeks after, are very much lowered to doctor excitement talk.
Anything better would be outstanding --- just never seen FDA jump in @ pre-clinical combo MOA.
Why are we not filing a mono MOA Request based on our a Ladies of Leronlimab? Maybe they do...who knows
5
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Greenlight Networks Expands Fiber Internet Services Greenlight Networks, a prominent fiber-to-the-home internet provider, is set to expand its fiber services into a new area with a significant investment of $100 million. This expansion aims to enhance high-speed internet access for residents and small businesses, ushering in new opportunities for economic growth and...
Continue Reading
Understanding Meta Platforms in the Market In the rapidly evolving business environment, it’s crucial for investors to closely examine firms prior to making investment choices. This article will provide a detailed analysis of Meta Platforms (NASDAQ: META) within the context of its main rivals in the Interactive Media & Services sector. By reviewing essential financial...
Continue Reading
Exploring Preliminary Data on Early Redemptions In light of recent financial insights, Jyske Realkredit has released preliminary data regarding early redemptions, specifically focusing on prepayments related to bonds. This intriguing announcement is intended for stakeholders and interested parties looking to understand the dynamics of the bond market. Understanding Early...
Continue Reading
Eltek Ltd. Announces Strong Performance for Q3 2024 Eltek Ltd. (NASDAQ: ELTK), a world-leading manufacturer of advanced printed circuit board solutions, has recently reported remarkable financial results for its third quarter, demonstrating a meaningful surge in revenues and profits. The company’s commitment to innovative practices in the PCB sector is reflected in its...
Continue Reading
Excitement Grows for Palantir Technologies' AI Conference As Palantir Technologies prepares for its upcoming conference focused on artificial intelligence, industry experts are eagerly anticipating the insights that could come from this significant event. A key topic of discussion is the recent extension of Palantir's partnership with a major energy player. Strategic...
Continue Reading